27601292|t|Voriconazole metabolism is influenced by severe inflammation: a prospective study
27601292|a|During an infection or inflammation, several drug - metabolizing enzymes in the liver are down-regulated, including cytochrome P450 iso-enzymes. Since voriconazole is extensively metabolized by cytochrome P450 iso-enzymes, the metabolism of voriconazole can be influenced during inflammation via reduced clearance of the drug, resulting in higher voriconazole trough concentrations. To investigate prospectively the influence of inflammation on voriconazole metabolism and voriconazole trough concent ratio ns. A prospective observational study was performed at the University Medical Center Groningen. Patients were eligible for inclusion if they were â‰¥18 years old and treated with voriconazole. Voriconazole and voriconazole-N-oxide concentrations were determined in discarded blood samples. To determine the degree of inflammation, C-reactive protein (CRP) concentrations were used. Subsequently, a longitudinal data analysis was performed to assess the effect of inflammation on the metabolic ratio and voriconazole trough concentration. Thirty-four patients were included. In total 489 voriconazole trough concentrations were included in the longitudinal data analysis. This analysis showed that inflammation, reflected by CRP concentrations, significantly influence d the metabolic ratio, voriconazole trough concentration and voriconazole-N-oxide concentration (all P < 0.001), when corrected for other factors that could influence voriconazole metabolism. The metabolic ratio was decreased by 0.99229(N) and the voriconazole-N-oxide concentration by 0.99775(N), while the voriconazole trough concentration was increased by 1.005321(N), where N is the difference in CRP units (in mg/L). This study shows that voriconazole metabolism is decreased during inflammation, resulting in higher voriconazole trough concentration s. Therefore, frequent monitoring of voriconazole serum concentrations is recommended during and following severe inflammation.
27601292	0	12	Voriconazole	T109,T121	C0393080
27601292	13	23	metabolism	T044	C0683140
27601292	27	37	influenced	T077	C4054723
27601292	41	47	severe	T080	C0205082
27601292	48	60	inflammation	T046	C0021368
27601292	64	81	prospective study	T062	C0033522
27601292	92	101	infection	T046	C3714514
27601292	105	117	inflammation	T046	C0021368
27601292	119	126	several	T081	C0443302
27601292	127	131	drug	T121	C1254351
27601292	134	146	metabolizing	T044	C0683140
27601292	147	154	enzymes	T116,T126	C0014442
27601292	162	167	liver	T023	C0023884
27601292	172	186	down-regulated	T044	C1327624
27601292	198	225	cytochrome P450 iso-enzymes	T116,T126	C0010762
27601292	233	245	voriconazole	T109,T121	C0393080
27601292	249	260	extensively	T080	C0205231
27601292	261	272	metabolized	T044	C0683140
27601292	276	303	cytochrome P450 iso-enzymes	T116,T126	C0010762
27601292	309	319	metabolism	T044	C0683140
27601292	323	335	voriconazole	T109,T121	C0393080
27601292	343	353	influenced	T077	C4054723
27601292	361	373	inflammation	T046	C0021368
27601292	378	385	reduced	T080	C0392756
27601292	386	407	clearance of the drug	T039	C0683151
27601292	422	428	higher	T080	C0205250
27601292	429	441	voriconazole	T109,T121	C0393080
27601292	442	463	trough concentrations	T081	C3640757
27601292	498	507	influence	T077	C4054723
27601292	511	523	inflammation	T046	C0021368
27601292	527	539	voriconazole	T109,T121	C0393080
27601292	540	550	metabolism	T044	C0683140
27601292	555	567	voriconazole	T109,T121	C0393080
27601292	568	591	trough concent ratio ns	T081	C3640757
27601292	583	588	ratio	T081	C0456603
27601292	595	626	prospective observational study	T062	C0033522
27601292	648	673	University Medical Center	T073,T093	C0000872
27601292	674	683	Groningen	T083	C0017446
27601292	685	693	Patients	T101	C0030705
27601292	699	707	eligible	T080	C1548635
27601292	712	721	inclusion	T080	C1512693
27601292	753	765	treated with	T061	C0332293
27601292	766	778	voriconazole	T109,T121	C0393080
27601292	780	792	Voriconazole	T109,T121	C0393080
27601292	797	817	voriconazole-N-oxide	T109,T121	C4263709
27601292	818	832	concentrations	T081	C1446561
27601292	862	875	blood samples	T031	C0178913
27601292	894	900	degree	T081	C0449286
27601292	904	916	inflammation	T046	C0021368
27601292	918	957	C-reactive protein (CRP) concentrations	T059	C0201657
27601292	985	1011	longitudinal data analysis	T062	C0023981
27601292	1029	1035	assess	T058	C0184514
27601292	1040	1046	effect	T080	C1280500
27601292	1050	1062	inflammation	T046	C0021368
27601292	1070	1079	metabolic	T044	C0683140
27601292	1080	1085	ratio	T081	C0456603
27601292	1090	1102	voriconazole	T109,T121	C0393080
27601292	1103	1123	trough concentration	T081	C3640757
27601292	1137	1145	patients	T101	C0030705
27601292	1174	1186	voriconazole	T109,T121	C0393080
27601292	1187	1208	trough concentrations	T081	C3640757
27601292	1230	1256	longitudinal data analysis	T062	C0023981
27601292	1263	1271	analysis	T062	C0023981
27601292	1284	1296	inflammation	T046	C0021368
27601292	1311	1329	CRP concentrations	T059	C0201657
27601292	1345	1354	influence	T077	C4054723
27601292	1361	1370	metabolic	T044	C0683140
27601292	1371	1376	ratio	T081	C0456603
27601292	1378	1390	voriconazole	T109,T121	C0393080
27601292	1391	1411	trough concentration	T081	C3640757
27601292	1416	1436	voriconazole-N-oxide	T109,T121	C4263709
27601292	1437	1450	concentration	T081	C1446561
27601292	1493	1500	factors	T169	C1521761
27601292	1512	1521	influence	T077	C4054723
27601292	1522	1534	voriconazole	T109,T121	C0393080
27601292	1535	1545	metabolism	T044	C0683140
27601292	1551	1560	metabolic	T044	C0683140
27601292	1561	1566	ratio	T081	C0456603
27601292	1571	1580	decreased	T081	C0205216
27601292	1603	1623	voriconazole-N-oxide	T109,T121	C4263709
27601292	1624	1637	concentration	T081	C1446561
27601292	1663	1675	voriconazole	T109,T121	C0393080
27601292	1676	1696	trough concentration	T081	C3640757
27601292	1701	1710	increased	T081	C0205217
27601292	1756	1759	CRP	T116,T129	C0006560
27601292	1799	1811	voriconazole	T109,T121	C0393080
27601292	1812	1822	metabolism	T044	C0683140
27601292	1826	1835	decreased	T081	C0205216
27601292	1843	1855	inflammation	T046	C0021368
27601292	1870	1876	higher	T080	C0205250
27601292	1877	1889	voriconazole	T109,T121	C0393080
27601292	1890	1910	trough concentration	T081	C3640757
27601292	1925	1933	frequent	T079	C0332183
27601292	1934	1944	monitoring	T058	C1283169
27601292	1948	1960	voriconazole	T109,T121	C0393080
27601292	1961	1981	serum concentrations	T081	C0683149
27601292	2018	2024	severe	T080	C0205082
27601292	2025	2037	inflammation	T046	C0021368